Prelude Capital Management’s Akero Therapeutics AKRO Stock Holding History

Prelude Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,101	Closed	-$907K	–	1272
2025 Q3	$907K	Buy	19,101 +29	+0.2%	+$1.4K	0.07%	330
2025 Q2	$1.02M	Sell	19,072 -4,918	-21%	-$223K	0.1%	256
2025 Q1	$971K	Buy	23,990 +6,118	+34%	+$259K	0.07%	314
2024 Q4	$497K	Buy	17,872 +1,572	+10%	+$47.6K	0.03%	594
2024 Q3	$468K	Buy	+16,300	New	+$425K	0.03%	658
2023 Q4	–	Sell	-11,243	Closed	-$569K	–	1110
2023 Q3	$569K	Buy	+11,243	New	+$523K	0.04%	431

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's AKRO Position: Q4 2025 in Review

Prelude Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 19,101 shares — an estimated $907K sold.

Prelude Capital Management first reported a position in AKRO in Q3 2023 and held it in 6 quarters. The position peaked at $1.02M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Prelude Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Prelude Capital Management sold 19,101 Akero Therapeutics shares in Q4 2025, an estimated $907K.
Prelude Capital Management first reported a position in Akero Therapeutics in Q3 2023 and held it in 6 quarters.
Prelude Capital Management's Akero Therapeutics position peaked at $1.02M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.